#$%^&*AU2018267662A120181213.pdf#####ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS ABSTRACT The invention provides a stable formulation comprising an anti-EGFR antibody drug conjugate (ADC), including an anti-EGFR antibody, e.g., antibody 1, conjugated to an auristatin, e.g., MMAF, histidine, a sugar, and a surfactant.